Summary
We investigated the effect of sodium valproate on plasma ACTH and serum cortisol concentrations in different pathological states of ACTH hypersecretion. Five patients with pituitary dependent Cushing's syndrome, two patients with Nelson's syndrome and five patients with Addison's disease were studied. Neither a single dose nor long term administration of sodium valproate resulted in a significant decrease of plasma ACTH levels in patients with Cushing's disease and Nelson's syndrome. Furthermore, the response of ACTH and cortisol to stimulation with lysine-vasopressin was unaffected during acute and chronic treatment. Patients with Addison's disease showed a slight attenuation of the ACTH response to lysine-vasopressin as compared to placebo but the difference was not statistically significant. In conclusion: sodium valproate does not appear to be effective in controlling ACTH hypersecretion in pituitary dependent Cushing's syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ACTH:
-
Adrenocorticotrophic hormone
- CRF:
-
Corticotropin releasing factor
References
Allolio B, Winkelmann W, Kaulen D, Hipp FX, Mies R (1982) Valproate in Cushing's syndrome. Lancet 1:171
Allolio B, Winkelmann W, Hipp FX (1982) Effect of meclastine, an H1-antihistamine, on plasma ACTH in adrenal insufficiency. Acta Endocrinol (Copenh) 96:98
Ambrosi B, Bochicchio D, Riva E, Faglia G (1983) Effects of sodium valproate administration on plasma ACTH levels in patients with ACTH hypersecretion. J Endocrinol Invest 6:305
Cavagnini F, Moitti C, Polli EE (1984) Sodium valproate in Cushing's disease. Lancet 2:162
Dornhorst A, Jenkins JS, Lamberts SWI, Abraham RR, Wynn V, Beckford U, Gillham B, Jones MT (1983) The evaluation of sodium valproate in the treatment of Nelson's syndrome. J Clin Endocrinol Metab 56:985
Elias AN, Gwinnup G, Valenta LJ (1981) Effects of valproic acid, naloxone and hydrocortisone in Nelson's syndrome and Cushing's disease. Clin Endocrinol 15:151
Grandison L, Cavagnini F, Schmid R, Invitti C, Goidotti A (1982) γ-aminobutyric acid and benzodiazepine-binding sites in human anterior pituitary. J Clin Endocrinol Metab 54:597
Jones MT, Hillhouse EW (1977) Neurotransmitter regulation of corticotrophin releasing factor in vitro. NY Acad Sci 297:536
Jones MT, Gillham B, Beckford U (1981) Effect of treatment with sodium valproate and diazepam on plasma corticotrophin in Nelson's syndrome. Lancet 1:1179
Koppeschaar HPF, Croughs RIM, Thijssen JHH, Schwarz F (1982) Sodium valproate and heterogeneity of pituitary dependent Cushing's syndrome. Lancet 1:1253
Koppeschaar HPF, Croughs RIM, Thijssen IHH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin Endocrinol 25:661
Krieger DT (1983) Physiopathology of Cushing's disease. Endocr Rev 4:22
Loli P, Berselli ME, Frascatani F, Muratori F, Tagliaferri M (1984) Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion. J Endocrinol Invest 7:93
Perry TJ, Hansen S (1978) Biochemical effects in man and rat of three drugs which can increase brain GABA content. J Neurochem 30:679
Van Cauter E, Refetoff S (1985) Evidence for 2 subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 312:1343
Voigt KH, Fehm HL, Reck R, Pfeiffer EF (1974) Spontaneous and stimulated secretion of Quso-extractable immunoassayble by ACTH in man. Klin Wochenschr 52:516
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reincke, M., Allolio, B., Kaulen, D. et al. The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease. Klin Wochenschr 66, 686–689 (1988). https://doi.org/10.1007/BF01726927
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01726927